September 2020 Volume 16, Issue 8

Volume 16, Issue 8 | September 2020

September 2020

In this Issue

Clinical Trials

Drug Discovery News Placeholder Image

Mighty micro PEA

Prospective COVID-19 treatment uses cannabinoid approach
Drug Discovery News Placeholder Image

In pursuit of emergency authorization

RedHill Biopharma accelerates Phase 2/3 COVID-19 drug opaganib program
Drug Discovery News Placeholder Image

ISA101b and Libtayo vs. oropharyngeal cancer

ISA Pharmaceuticals strengthens strategic immuno-oncology collaboration with Regeneron
Drug Discovery News Placeholder Image

Research highlights potential of Akero’s NASH candidate

Patients treated with efruxifermin show improvements in markers of insulin sensitivity and lipoprotein metabolism
Drug Discovery News Placeholder Image

Hopes on the rise in wake of ASCENT data

Immunomedics shares strong data for Trodelvy in triple-negative breast cancer

Discovery

Drug Discovery News Placeholder Image

Quantum (computing) gains

Drug discovery expected to be one of the first beneficiaries of technology
Drug Discovery News Placeholder Image

Where AI meets biology

TARA and VentAI collaborate on drug discovery
Drug Discovery News Placeholder Image

Human-on-a-Chip system models Alzheimer’s

Publication validates potential of drug discovery platform to study early stages of disease pathology
Drug Discovery News Placeholder Image

An ‘exquisitely selective’ tool

Mission Therapeutics and Imperial College London report on deubiquitylating enzyme probe
Drug Discovery News Placeholder Image

Welcoming the fourth wave of drug discovery

Amgen executive forecasts multispecific drugs as the next key movement

Business & Government Policy

Drug Discovery News Placeholder Image

Q&A: Another look at aducanumab

ProMIS Neurosciences’ CMO talks with DDN about why Biogen restarted its Alzheimer’s disease program
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Interplay between obviousness and satisfaction invalidates claims in Biogen Tecfidera patent

The same evidence that supports non-obviousness for patentability can also restrict the scope of what has been described

Research & Development

Drug Discovery News Placeholder Image

Gaining ground with Gemini

In-silico patient model moves industry a step closer to understanding human disease
Drug Discovery News Placeholder Image

Leveraging lentivirals

Magenta Therapeutics joins with AVROBIO to evaluate a combination approach to gene therapy
Drug Discovery News Placeholder Image

Orchard and GSK announce license agreements

New agreements will benefit patients with WAS and TDT
Drug Discovery News Placeholder Image

Tracking down gene fusions

Stanford researchers use single-cell statistical modeling method to go after cancer

Contract Services

Drug Discovery News Placeholder Image

A faster new product pathway

LGM Pharma acquires Nexgen Pharma’s CDMO operations
Drug Discovery News Placeholder Image

Integrated services for COVID and more

CaprionX-HistoGeneX and Viroclinics-DDL to offer complementary services for infectious disease research and therapeutics
Drug Discovery News Placeholder Image

Mid-Size CRO steps up

Pharm-Olam positioning organization for growth trajectory

Diagnostics

Drug Discovery News Placeholder Image

Exhaled biomarkers reveal lung disease

Nanoparticles create a ‘breath signal’ that could be used to diagnose infectious or genetic diseases
Drug Discovery News Placeholder Image

Antigens for SARS-CoV-2

LGC acquires NAC, one of first to offer antigens for novel coronavirus
Drug Discovery News Placeholder Image

Critical for cancer

U.K.-Italy collaboration aims for precision oncology at scale
Drug Discovery News Placeholder Image

Trying to meet coronavirus demands

NIH awards nearly $249M into new COVID-19 testing technologies

Preclinical

Drug Discovery News Placeholder Image

Can a vaccine prevent type 1 diabetes?

Provention Bio advances work on coxsackievirus B vaccine
Drug Discovery News Placeholder Image

A (natural) killer match

Kiadis, Sanofi ink license agreement for natural killer therapeutics

Editor's Focus

Editor’s Focus: Alzheimer’s looms large in neuroscience

Market research suggests that neurology-related pharma and biotech R&D is going to be dominated by Alzheimer's disease for some time

Commentary

Drug Discovery News Placeholder Image

Innovating scientific conferences

More meetings are going virtual, and that may very well be a good thing even after COVID is no longer a pandemic
Drug Discovery News Placeholder Image

Guest Commentary: Automation software improves speed and accuracy of cell line production

Innovative lab software automates scheduling, hit-picking and liquid transfer to boost walkaway time

Special Reports

Drug Discovery News Placeholder Image

Special Report on Stem Cells: Mother lode

Are cancer stem cells a better oncology target?

Feature

Drug Discovery News Placeholder Image

Focus Feature on Neuroscience

The Society for Nueroscience meeting may have been called off this year, but DDN has a large roundup of recent news of neurological R&D to share in its place, from aging insights via sea urchins to machine learning advances to putting antibodies to work in treating neurodegeneration (and more)
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue